(Q37795877)

23 August 2017

title

Liraglutide: effects beyond glycaemic control in diabetes treatment (English)

1 reference

23 August 2017

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20887302

24 July 2024

author name string

J. B. McGill

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20887302

24 July 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20887302

24 July 2024

publication date

1 October 2010

1 reference

full work available at URL

23 August 2017

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1742-1241.2010.02495.x

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20887302

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1742-1241.2010.02495.x

24 July 2024

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1742-1241.2010.02495.x/fullpdf

24 July 2024

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

International journal of clinical practice. Supplement

24 July 2024

published in

1 reference

23 August 2017

issue

167

1 reference

23 August 2017

page(s)

28-34

1 reference

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02495.X

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

21 January 2018

1

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

24 July 2024

2

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

24 July 2024

3

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

24 July 2024

4

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

24 July 2024

5

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

24 July 2024

6

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

24 July 2024

7

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

24 July 2024

8

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

Clustering of metabolic factors and coronary heart disease

24 July 2024

9

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes.

24 July 2024

10

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

24 July 2024

Q22242898

11

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: the Framingham Heart Study

24 July 2024

12

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

Visceral adiposity and its anatomical distribution as predictors of the metabolic syndrome and cardiometabolic risk factor levels

24 July 2024

13

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

Increased food energy supply is more than sufficient to explain the US epidemic of obesity.

24 July 2024

14

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

Contributions of insulin-resistance and insulin-secretory defects to the pathogenesis of type 2 diabetes mellitus

24 July 2024

15

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

Adipose tissue as an endocrine organ

24 July 2024

16

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

Associations of adiponectin, resistin, and tumor necrosis factor-alpha with insulin resistance

24 July 2024

17

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

Visceral obesity and plasma glucose-insulin homeostasis: contributions of interleukin-6 and tumor necrosis factor-alpha in men.

24 July 2024

18

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

Insulin resistance and pancreatic beta cell failure

24 July 2024

19

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

Emerging concepts in the medical and surgical treatment of obesity

24 July 2024

20

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

Obesity and disease management: effects of weight loss on comorbid conditions

24 July 2024

21

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

24 July 2024

22

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus

24 July 2024

23

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study

24 July 2024

24

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

24 July 2024

25

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents.

24 July 2024

26

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents

24 July 2024

28

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

24 July 2024

29

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

24 July 2024

31

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

24 July 2024

32

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans

24 July 2024

33

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes

24 July 2024

34

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

24 July 2024

35

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

Biology of incretins: GLP-1 and GIP

24 July 2024

36

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

24 July 2024

38

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

24 July 2024

39

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials

24 July 2024

40

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension

24 July 2024

41

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men.

24 July 2024

42

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

24 July 2024

43

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study

24 July 2024

44

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

Impact of sitagliptin on markers of beta-cell function: a meta-analysis

24 July 2024

45

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database

24 July 2024

46

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone

24 July 2024

47

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02495.X

24 July 2024

Identifiers

1 reference

23 August 2017

1 reference